Cell News and Research

RSS

Researchers identify how Tissue Factor contributes to cancer growth

A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.

27 Oct 2009

Princeton University scientists and researchers team up to explore cancer evolution

Princeton University physical scientists will partner with researchers at four other institutions to explore the driving forces behind the evolution of cancer under a five-year, $15.2 million award from the National Cancer Institute.

27 Oct 2009

Mechanisms to control protein organization and cell-cell interaction in the immune system discovered

In a process essential to the immune system's response to infection, dendritic cells responsible for identifying pathogens communicate with the T-cells that destroy the infectious agents. To achieve this, the dendritic cells must be correctly activated and migrate to the lymph nodes where they must adhere firmly to T-cells.

27 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

NCI funds new Center on Microenvironment and Metastasis to research on cancer

Adding potent research firepower and fresh physical perspectives to combat cancer, the National Cancer Institute (NCI) has funded the new Center on the Microenvironment and Metastasis, which will be headquartered at Cornell University.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

Researchers show link between alcohol and cancer

Alcohol consumption has long been linked to cancer and its spread, but the underlying mechanism has never been clear.

27 Oct 2009

National Cancer Institute awards Johns Hopkins $14.8 million for cancer research

Researchers from the Johns Hopkins Institute for NanoBioTechnology have been awarded $14.8 million from the National Cancer Institute to launch a research center aimed at unraveling the physical underpinnings of the growth and spread of cancer.

26 Oct 2009

Cephalon, BDC sign option agreement

Cephalon, Inc. and BioAssets Development Corporation (BDC), a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC.

26 Oct 2009

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

26 Oct 2009

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

26 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen’s DAC Blockers Platform and reviewed disease model data for selected product candidates.

26 Oct 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009

Ingenuity Systems and Life Technologies develop new gene expression workflow for cell transcriptome analysis

Ingenuity Systems, the leading provider of information solutions for life science researchers, today announced it has developed a new gene expression workflow with Life Technologies Corporation.

26 Oct 2009

SuperGen and GSK team up to discover and develop cancer therapeutics based on epigenetic targets

SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.

26 Oct 2009

Canadian cardiologists, oncologists team up to fight breast cancer

A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

Researchers at Children's Hospital Boston report that an enzyme known as Mst3b, previously identified in their lab, is essential for regenerating damaged axons (nerve fibers) in a live animal model, in both the peripheral and central nervous systems.

26 Oct 2009

Novel protein responsible for changing DNA structure and silencing the expression of genes identified

A study published recently in the Proceedings of the National Academy of Science (PNAS) by a team of scientists headed by Professors Hélène Bierne and Pascale Cossart from the Pasteur Institute, in collaboration with colleagues form the CNRS and the French Agricultural Research Institute (INRA), identified a novel protein, BAHD1, which is responsible for changing DNA structure and silencing the expression of genes.

26 Oct 2009

Potential link exists between histone mRNA formation and apoptosis

A study from the University of North Carolina at Chapel Hill has identified a key player in a molecular process essential for DNA replication within cells.

26 Oct 2009

Cell News and Research

Researchers identify how Tissue Factor contributes to cancer growth

Princeton University scientists and researchers team up to explore cancer evolution

Mechanisms to control protein organization and cell-cell interaction in the immune system discovered

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

NCI funds new Center on Microenvironment and Metastasis to research on cancer

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

Researchers show link between alcohol and cancer

National Cancer Institute awards Johns Hopkins $14.8 million for cancer research

Cephalon, BDC sign option agreement

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

Results from Phase I dose-escalation study of AT-101 announced

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Anti-viral drug development programs progress successfully, reports NanoViricides

Ingenuity Systems and Life Technologies develop new gene expression workflow for cell transcriptome analysis

SuperGen and GSK team up to discover and develop cancer therapeutics based on epigenetic targets

Canadian cardiologists, oncologists team up to fight breast cancer

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

Novel protein responsible for changing DNA structure and silencing the expression of genes identified

Potential link exists between histone mRNA formation and apoptosis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News